Cargando…

Identifying patients at risk: multi‐centre comparison of HeartMate 3 and HeartWare left ventricular assist devices

AIMS: Since the withdrawal of HeartWare (HVAD) from the global market, there is an ongoing discussion if and which patients require prophylactically exchange for a HeartMate 3 (HM3). Therefore, it is important to study outcome differences between HVAD and HM3 patients. Because centres differ in pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Numan, Lieke, Zimpfer, Daniel, Zadok, Osnat Itzhaki Ben, Aarts, Emmeke, Morshuis, Michiel, Guenther, Sabina P.W., Riebandt, Julia, Wiedemann, Dominik, Ramjankhan, Faiz Z., Oppelaar, Anne‐Marie, Ben‐Gal, Tuvia, Ben‐Avraham, Binyamin, Asselbergs, Folkert W., Schramm, Rene, Van Laake, Linda W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192248/ https://www.ncbi.nlm.nih.gov/pubmed/36798028 http://dx.doi.org/10.1002/ehf2.14308

Ejemplares similares

Propensity score‐based analysis of long‐term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support
por: Numan, Lieke, et al.
Publicado: (2021)

Survival after HeartMate 3 left ventricular assist device implantation: real‐world data from Europe
por: Numan, Lieke, et al.
Publicado: (2023)

Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3®
por: Schramm, Rene, et al.
Publicado: (2020)

The History of Durable Left Ventricular Assist Devices and Comparison of Outcomes: HeartWare, HeartMate II, HeartMate 3, and the Future of Mechanical Circulatory Support
por: Berardi, Cecilia, et al.
Publicado: (2022)

Comparison of left ventricular geometry after HeartMate II and HeartWare left ventricular assist device implantation
por: Hosseini, Morteza Tavakkoli, et al.
Publicado: (2013)

Successful repeated thrombolysis in a patient with HeartWare thrombosis – the importance of Doppler flow pattern
por: Paluszkiewicz, Lech, et al.
Publicado: (2014)

Identification of characteristics, risk factors, and predictors of recurrent LVAD thrombosis: conditions in HeartWare devices
por: Gyoten, Takayuki, et al.
Publicado: (2020)

Is flow really continuous in last generation continuous flow Ventricular Assist Devices? A comparison between HeartMate II and HeartWare HVAD
por: Melisurgo, G, et al.
Publicado: (2012)

Flow dynamics during the HeartWare HVAD to HeartMate 3 exchange: A computational study assessing differential graft lengths and surgical techniques
por: Grinstein, Jonathan, et al.
Publicado: (2022)

HeartWare Thrombosis After mRNA COVID-19 Vaccination
por: Schettle, Sarah, et al.
Publicado: (2022)

Evolution of thrombolytic therapy in patients with HeartWare ventricular assist device thrombosis: a single-institutional experience
por: Fox, Henrik, et al.
Publicado: (2022)

Treatment of device thrombus in the HeartWare HVAD: surgical exchange through thoracotomy
por: Ghandour, Amale, et al.
Publicado: (2021)

Design Concepts and Preclinical Results of a Miniaturized HeartWare Platform: The MVAD System
por: Cheung, Anson, et al.
Publicado: (2015)

A rare case of Takotsubo syndrome in a patient 5 months after heart transplantation
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019)

Early thrombus formation in patient with HeartWare left ventricular assist device presenting with acute heart failure
por: Ucar, Mustafa, et al.
Publicado: (2016)

Octreotide for the Management of Gastrointestinal Bleeding in a Patient with a HeartWare Left Ventricular Assist Device
por: Dang, Geetanjali, et al.
Publicado: (2014)

Effects of HeartWare ventricular assist device on the von Willebrand factor: results of an academic Belgian center
por: Esmaeilzadeh, Fatemeh, et al.
Publicado: (2016)

Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry
por: Francica, Alessandra, et al.
Publicado: (2023)

Self‐care behaviours of patients with left ventricular assist devices in Israel: changes during the COVID‐19 pandemic
por: Melnikov, Semyon, et al.
Publicado: (2023)

Successful bridge to recovery using two-stage HeartWare LVAD explantation approach after embolic stroke
por: Sabashnikov, Anton, et al.
Publicado: (2013)

Corrigendum: Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry
por: Francica, Alessandra, et al.
Publicado: (2023)

First successful percutaneous treatment of a totally occluded HeartWare outflow graft: Case report and literature review
por: Kemaloğlu, Cemal, et al.
Publicado: (2018)

Emergency HeartWare Ventricular Assist Device (HVAD) exchange due to pump thrombosis using minimally invasive technique
por: Antończyk, Remigiusz, et al.
Publicado: (2017)

Developing a personalized remote patient monitoring algorithm: a proof-of-concept in heart failure
por: Moazeni, Mehran, et al.
Publicado: (2023)

Heartmate 3 as a bridge to heart transplantation in a patient with congenitally corrected transposition of the great arteries: a case report
por: Barac, Yaron D., et al.
Publicado: (2022)

Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2022)

Inflow cannula position as risk factor for stroke in patients with HeartMate 3 left ventricular assist devices
por: Schlöglhofer, Thomas, et al.
Publicado: (2022)

Use of Intracorporeal Durable LVAD Support in Children Using HVAD or HeartMate 3—A EUROMACS Analysis
por: Schweiger, Martin, et al.
Publicado: (2023)

Exergaming in patients with a left ventricular assist device: a feasibility study
por: Hammer, Yoav, et al.
Publicado: (2022)

Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2017)

Interpreting Neurologic Outcomes in a Changing Trial Design Landscape: An Analysis of HeartWare Left Ventricular Assist Device Using a Hybrid Intention to Treat Population
por: Mahr, Claudius, et al.
Publicado: (2019)

Monitoring left ventricular assist device parameters to detect flow- and power-impacting complications: a proof of concept
por: Moazeni, Mehran, et al.
Publicado: (2023)

A Picture Is Worth 2,000 Words
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2023)

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019)

Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure –1 year results from the Ce mark trial
por: Krabatsch, Thomas, et al.
Publicado: (2017)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

Health‐related quality of life in left ventricular assist device‐supported patients
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2021)

Cardiomyopathy associated with Ceutzfeld–Jakob disease: a diagnosis of exclusion: a case report
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2020)

A rise in left atrial pressure detected by the V‐LAP™ system for patients with heart failure during the coronavirus disease 2019 pandemic
por: Perl, Leor, et al.
Publicado: (2020)

Accuracy of Doppler blood pressure measurement in HeartMate 3 ventricular assist device patients
por: Li, Song, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gcfq7bsgcpuuk9lekev5icpc36